- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00358748
Early Use of Hydrocortisone in Hypotensive Very Low Birth Weight Infants
The purpose of this study is to investigate the early use of hydrocortisone in hypotensive very low birth weight infants.
Based on the observations that:
- hypotension is a common problem in very low birthweight infants and is associated with brain injury and poor neurological outcomes;
- some infants are refractory to standard treatment (volume expansion and vasopressors), which is not exempt of adverse effects;
- relative adrenal insufficiency has been described in this population; we hypothesize that hydrocortisone is effective in the treatment of hypotension in this population and reduce the need for vasopressors.
Study Overview
Detailed Description
Eligible infants will be randomly assigned to receive hydrocortisone or placebo, using sequentially numbered, preassigned treatment designations in sealed, opaque envelopes. The study drug will be randomly assigned to each patient number, in advance, using a computer-based random number generator.
Hydrocortisone and placebo doses will be prepared and provided by the hospital pharmacy following the assigned study number. Active and placebo drug solutions will be completely indistinguishable.
Infants of multiple gestations will be randomized as separate subjects. Crossover between study groups is not allowed. Physicians involved in the care of the infants will be blinded to treatment group allocation.
If the infant remains hypotensive after a Normal Saline (NS) bolus 10 ml/kg, blood for serum cortisol level determination will be drawn and hydrocortisone or an equivalent volume of NS placebo will be administered intravenously as follows: first dose immediately after randomization 2 mg/kg; 6 hours after 1 mg/kg q6h for 3 doses; followed by 0.5 mg/kg q6hs for 4 doses. If an infant responds to the initial dose of NS but becomes hypotensive within 1 hour after will also be randomized, otherwise another NS bolus could be administered.
Initiation and escalation of inotropes:
Concurrently with the first dose of study drug, dopamine infusion will be started at 5 mcg/kg/minute, increasing stepwise to a maximum of 15 mcg/kg/minute. If hypotension persists an epinephrine infusion at 0.05 mcg/kg/min will be added and increased stepwise if necessary. The aim is to maintain mean blood pressure (MBP) above the hypotensive limit defined in the inclusion criteria.
Weaning of inotropes:
Once normotension has been maintained for 1 hour or MBP > 40 mmHg for 15 minutes, weaning should be started. Dopamine infusion will be reduced first, as tolerated, to 5 mcg/kg/minute. If the subject is on epinephrine infusion the dose will be reduced stepwise to 0.05 mcg/kg/minute and discontinued. When the subject is off epinephrine and/or dopamine at 5 mcg/kg/minute, dopamine will be discontinued. If at any time hypotension recurs, weaning should be held and increased inotropes dose as per escalation algorithm.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada
- Division of Neonatology, Children's and Women's Health Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Gestational age ≤ 30 weeks, Birth weight ≤ 1250 grams and ≤ 48 hours age;
- Umbilical or peripheral arterial catheter in place;
- Invasive mean blood pressure < gestational age in completed weeks after 1 Normal Saline bolus 10 ml/kg;
- Parental/legal guardian consent.
Exclusion Criteria:
- Clear evidence of hypovolemia (blood loss);
- Chromosomal abnormalities;
- Hydrops fetalis;
- Major congenital anomalies;
- Cardiac lesions other than patent ductus arteriosus.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Total cumulative dose of dopamine at 48 hours of study drug administration and by day 7 of life
Time Frame: 7 days
|
7 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Total cumulative dose of epinephrine and total dose of fluids at 48 hours of study drug administration and by day 7 of life
Time Frame: 7 days
|
7 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Horacio Osiovich, MD, The University of British Columbia
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- C05-0006
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neonatal Hypotension
-
Seoul National University HospitalNot yet recruitingHypotension | Intraoperative Complications | Neonatal Hypotension
-
Mount Sinai Hospital, CanadaThe Hospital for Sick Children; Sunnybrook Health Sciences Centre; University... and other collaboratorsRecruitingLate-Onset Neonatal Sepsis | Neonatal Hypotension | Extreme PrematurityCanada, United States, Ireland, Israel
-
University of IowaNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...Active, not recruitingHypotension | Neonatal PrematurityUnited States
-
Vincenzo CannizzaroCompletedArterial Hypotension in Critically Ill Neonatal and Pediatric PatientsSwitzerland
-
King George's Medical UniversityIndian Council of Medical ResearchCompletedNeonatal Morbidity | Neonatal IllnessesIndia
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Edwards LifesciencesCompletedHypotension | Intraoperative Hypotension | Postoperative HypotensionNetherlands
-
University of AarhusCompletedUncomplicated Neonatal HyperbilirubinemiaDenmark
-
Guangzhou Women and Children's Medical CenterRecruitingNeonatal Hyperbilirubinemia | Neonatal Jaundice | Hemolysis NeonatalChina
-
James J. Peters Veterans Affairs Medical CenterCompleted
-
Attikon HospitalRecruitingHypotension During Surgery | Prevention of HypotensionGreece
Clinical Trials on Hydrocortisone
-
Assistance Publique - Hôpitaux de ParisCompletedBronchopulmonary DysplasiaFrance
-
Horus UniversityRecruitingSubacromial Impingement Syndrome | Impingement SyndromeEgypt
-
University Hospital Southampton NHS Foundation...Imperial College London; University of Bristol; University Hospitals Bristol... and other collaboratorsCompleted
-
Ulla Feldt-RasmussenUnknown
-
University of VersaillesAssistance Publique - Hôpitaux de ParisTerminatedPneumonia, Viral | Influenza in HumansFrance
-
Vastra Gotaland RegionSahlgrenska University Hospital, Sweden; The Gothenburg Society of Medicine; Åke... and other collaboratorsNot yet recruitingDiabetes Mellitus | Adrenal Insufficiency | Polyglandular Autoimmune SyndromeSweden
-
Central Institute of Mental Health, MannheimGerman Research FoundationCompletedPosttraumatic Stress DisorderGermany
-
Ludwig-Maximilians - University of MunichCompletedSystemic Inflammatory Response Syndrome | Posttraumatic Stress DisorderGermany
-
Jerry ZimmermanEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingSeptic ShockUnited States, Canada, China, Israel, Japan, Malaysia, Pakistan, Saudi Arabia, Singapore, Vietnam
-
Haukeland University HospitalUnknownUltradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal HyperplasiaAddison Disease | Adrenal Hyperplasia CongenitalNorway